TY - JOUR
T1 - Correlates of human papillomavirus (HPV) vaccination initiation and completion among 18-26 year olds in the United States
AU - Boakye, Eric Adjei
AU - Lew, Daphne
AU - Muthukrishnan, Meera
AU - Tobo, Betelihem B.
AU - Rohde, Rebecca L.
AU - Varvares, Mark A.
AU - Osazuwa-Peters, Nosayaba
N1 - Funding Information:
The abstract was presented at the 2017 American Society for Cancer Research (AACR) in Washington DC.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/5/28
Y1 - 2018/5/28
N2 - Purpose: To examine correlates of HPV vaccination uptake in a nationally representative sample of 18-26-year-old adults. Methods: Young adults aged 18-26 years were identified from the 2014 and 2015 National Health Interview Survey (n D 7588). Survey-weighted multivariable logistic regression models estimated sociodemographic factors associated with HPV vaccine initiation (≥1 dose) and completion (≥3 doses). Results: Approximately 27% of study participants had initiated the HPV vaccine and 16% had completed the HPV vaccine. Participants were less likely to initiate the vaccine if they were men [(adjusted odds ratio) 0.19; (95% confidence interval) 0.16-0.23], had a high school diploma (0.40; 0.31-0.52) or less (0.46; 0.32-0.64) vs. college graduates, and were born outside the United States (0.52; 0.40-0.69). But, participants were more likely to initiate the HPV vaccine if they visited the doctor’s office 1-5 times (2.09; 1.56-2.81), or ≥ 6 times (1.86; 1.48-2.34) within the last 12 months vs. no visits. Odds of completing HPV vaccine uptake followed the same pattern as initiation. And after stratifying the study population by gender and foreignborn status, these variables remained statistically significant. Conclusions: In our nationally representative study, only one out of six 18-26 year olds completed the required vaccine doses. Men, individuals with high school or less education, and those born outside the United States were less likely to initiate and complete the HPV vaccination. Our findings suggest that it may be useful to develop targeted interventions to promote HPV vaccination among those in the catchup age range.
AB - Purpose: To examine correlates of HPV vaccination uptake in a nationally representative sample of 18-26-year-old adults. Methods: Young adults aged 18-26 years were identified from the 2014 and 2015 National Health Interview Survey (n D 7588). Survey-weighted multivariable logistic regression models estimated sociodemographic factors associated with HPV vaccine initiation (≥1 dose) and completion (≥3 doses). Results: Approximately 27% of study participants had initiated the HPV vaccine and 16% had completed the HPV vaccine. Participants were less likely to initiate the vaccine if they were men [(adjusted odds ratio) 0.19; (95% confidence interval) 0.16-0.23], had a high school diploma (0.40; 0.31-0.52) or less (0.46; 0.32-0.64) vs. college graduates, and were born outside the United States (0.52; 0.40-0.69). But, participants were more likely to initiate the HPV vaccine if they visited the doctor’s office 1-5 times (2.09; 1.56-2.81), or ≥ 6 times (1.86; 1.48-2.34) within the last 12 months vs. no visits. Odds of completing HPV vaccine uptake followed the same pattern as initiation. And after stratifying the study population by gender and foreignborn status, these variables remained statistically significant. Conclusions: In our nationally representative study, only one out of six 18-26 year olds completed the required vaccine doses. Men, individuals with high school or less education, and those born outside the United States were less likely to initiate and complete the HPV vaccination. Our findings suggest that it may be useful to develop targeted interventions to promote HPV vaccination among those in the catchup age range.
KW - 18-26 year olds
KW - Foreign-born status
KW - Gender disparities
KW - HPV vaccine
KW - HPV vaccine initiation and completion
KW - Human papillomavirus
KW - NHIS
KW - Young Adults
UR - http://www.scopus.com/inward/record.url?scp=85047923152&partnerID=8YFLogxK
U2 - 10.1080/21645515.2018.1467203
DO - 10.1080/21645515.2018.1467203
M3 - Article
C2 - 29708826
AN - SCOPUS:85047923152
SN - 2164-5515
VL - 14
SP - 2016
EP - 2024
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 8
ER -